These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 21642448)

  • 1. Increased folding and channel activity of a rare cystic fibrosis mutant with CFTR modulators.
    Caldwell RA; Grove DE; Houck SA; Cyr DM
    Am J Physiol Lung Cell Mol Physiol; 2011 Sep; 301(3):L346-52. PubMed ID: 21642448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules.
    Van Goor F; Straley KS; Cao D; González J; Hadida S; Hazlewood A; Joubran J; Knapp T; Makings LR; Miller M; Neuberger T; Olson E; Panchenko V; Rader J; Singh A; Stack JH; Tung R; Grootenhuis PD; Negulescu P
    Am J Physiol Lung Cell Mol Physiol; 2006 Jun; 290(6):L1117-30. PubMed ID: 16443646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.
    Amico G; Brandas C; Moran O; Baroni D
    Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CFTR potentiators partially restore channel function to A561E-CFTR, a cystic fibrosis mutant with a similar mechanism of dysfunction as F508del-CFTR.
    Wang Y; Liu J; Loizidou A; Bugeja LA; Warner R; Hawley BR; Cai Z; Toye AM; Sheppard DN; Li H
    Br J Pharmacol; 2014 Oct; 171(19):4490-503. PubMed ID: 24902474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanistic Approaches to Improve Correction of the Most Common Disease-Causing Mutation in Cystic Fibrosis.
    Bali V; Lazrak A; Guroji P; Matalon S; Bebok Z
    PLoS One; 2016; 11(5):e0155882. PubMed ID: 27214033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of a hybrid potentiator-corrector agonist of the cystic fibrosis mutant protein DeltaF508-CFTR.
    Mills AD; Yoo C; Butler JD; Yang B; Verkman AS; Kurth MJ
    Bioorg Med Chem Lett; 2010 Jan; 20(1):87-91. PubMed ID: 19954980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyanoquinolines with independent corrector and potentiator activities restore ΔPhe508-cystic fibrosis transmembrane conductance regulator chloride channel function in cystic fibrosis.
    Phuan PW; Yang B; Knapp JM; Wood AB; Lukacs GL; Kurth MJ; Verkman AS
    Mol Pharmacol; 2011 Oct; 80(4):683-93. PubMed ID: 21730204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thermally unstable gating of the most common cystic fibrosis mutant channel (ΔF508): "rescue" by suppressor mutations in nucleotide binding domain 1 and by constitutive mutations in the cytosolic loops.
    Wang W; Okeyo GO; Tao B; Hong JS; Kirk KL
    J Biol Chem; 2011 Dec; 286(49):41937-41948. PubMed ID: 21965669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct interaction of a small-molecule modulator with G551D-CFTR, a cystic fibrosis-causing mutation associated with severe disease.
    Pasyk S; Li C; Ramjeesingh M; Bear CE
    Biochem J; 2009 Feb; 418(1):185-90. PubMed ID: 18945216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deletion of phenylalanine 508 causes attenuated phosphorylation-dependent activation of CFTR chloride channels.
    Wang F; Zeltwanger S; Hu S; Hwang TC
    J Physiol; 2000 May; 524 Pt 3(Pt 3):637-48. PubMed ID: 10790148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probing conformational rescue induced by a chemical corrector of F508del-cystic fibrosis transmembrane conductance regulator (CFTR) mutant.
    Yu W; Kim Chiaw P; Bear CE
    J Biol Chem; 2011 Jul; 286(28):24714-25. PubMed ID: 21602569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elexacaftor Mediates the Rescue of F508del CFTR Functional Expression Interacting with MSD2.
    Bongiorno R; Ludovico A; Moran O; Baroni D
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cystic fibrosis transmembrane conductance regulator (CFTR) and renal function.
    Stanton BA
    Wien Klin Wochenschr; 1997 Jun; 109(12-13):457-64. PubMed ID: 9261986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two Small Molecules Restore Stability to a Subpopulation of the Cystic Fibrosis Transmembrane Conductance Regulator with the Predominant Disease-causing Mutation.
    Meng X; Wang Y; Wang X; Wrennall JA; Rimington TL; Li H; Cai Z; Ford RC; Sheppard DN
    J Biol Chem; 2017 Mar; 292(9):3706-3719. PubMed ID: 28087700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the F508del mutation on ovine CFTR, a Cl- channel with enhanced conductance and ATP-dependent gating.
    Cai Z; Palmai-Pallag T; Khuituan P; Mutolo MJ; Boinot C; Liu B; Scott-Ward TS; Callebaut I; Harris A; Sheppard DN
    J Physiol; 2015 Jun; 593(11):2427-46. PubMed ID: 25763566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A small-molecule modulator interacts directly with deltaPhe508-CFTR to modify its ATPase activity and conformational stability.
    Wellhauser L; Kim Chiaw P; Pasyk S; Li C; Ramjeesingh M; Bear CE
    Mol Pharmacol; 2009 Jun; 75(6):1430-8. PubMed ID: 19339490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An overview on chemical structures as ΔF508-CFTR correctors.
    Spanò V; Montalbano A; Carbone A; Scudieri P; Galietta LJV; Barraja P
    Eur J Med Chem; 2019 Oct; 180():430-448. PubMed ID: 31326599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CFTR: folding, misfolding and correcting the ΔF508 conformational defect.
    Lukacs GL; Verkman AS
    Trends Mol Med; 2012 Feb; 18(2):81-91. PubMed ID: 22138491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms for rescue of correctable folding defects in CFTRDelta F508.
    Grove DE; Rosser MF; Ren HY; Naren AP; Cyr DM
    Mol Biol Cell; 2009 Sep; 20(18):4059-69. PubMed ID: 19625452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antihypertensive 1,4-dihydropyridines as correctors of the cystic fibrosis transmembrane conductance regulator channel gating defect caused by cystic fibrosis mutations.
    Pedemonte N; Diena T; Caci E; Nieddu E; Mazzei M; Ravazzolo R; Zegarra-Moran O; Galietta LJ
    Mol Pharmacol; 2005 Dec; 68(6):1736-46. PubMed ID: 16150931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.